Superworth

Acrivon Therapeutics EPS ACRV

Diluted earnings per share by quarter and over the last twelve months, from 2021.

Last 12 months, to Jun 30, 2026
−$1.88
Latest quarter, Q2 FY26
−$0.43
Fiscal year 2025
−$2.02

Acrivon Therapeutics' earnings per share was −$1.88 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.43.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$2.02n/a
FY2024−$2.44n/a
FY2023−$2.73n/a
FY2022−$13.34n/a
FY2021n/an/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.43n/a−$1.88
Q1 FY26−$0.49n/a−$2.00
Q4 FY25−$0.49n/a−$2.02
Q3 FY25−$0.47n/a−$2.13
Q2 FY25−$0.55n/a−$2.25
Q1 FY25−$0.51n/a−$2.22
Q4 FY24−$0.60n/a−$2.44
Q3 FY24−$0.59n/a−$2.70
Q2 FY24−$0.52n/a−$2.77
Q1 FY24−$0.73n/a−$2.88
Q4 FY23−$0.86n/a−$2.73
Q3 FY23−$0.66n/a−$2.67

Against its peers

Companies in Drug Manufacturers - General nearest Acrivon Therapeutics' size, closest first, today.

CompanyEPS, 12 monthsGrowth
ACRVAcrivon Therapeutics−$1.88
LFVNLifevantage$0.40−46% a year
SPROSpero Therapeutics$0.11
ATNMActinium Pharmaceuticals$0.36
NATRNatures Sunshine Products$1.01+36% a year
ARVNArvinas$0.16
PBYIPuma Biotechnology$0.52−47% a year
IRWDIronwood Pharmaceuticals$0.77
ZVRAZevra Therapeutics$0.93
CRMDCorMedix$2.13+184% a year
Peer median$0.52

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Acrivon Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.